<DOC>
	<DOCNO>NCT00002925</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Some cancer may become resistant chemotherapy drug . Combining PSC 833 chemotherapy may reduce resistance drug allow cancer cell kill . Interleukin-2 may stimulate person 's white blood cell kill leukemia cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy plus PSC 833 follow additional chemotherapy peripheral stem cell transplantation interleukin-2 treating patient untreated acute myelogenous leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Plus PSC 833 Followed Interleukin-2 Treating Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) daunorubicin use combination etoposide , cytarabine , PSC 833 ( ADEP ) , combination etoposide cytarabine ( ADE ) previously untreated patient acute myelogenous leukemia le 60 year . II . Determine MTD etoposide use combination constant dose daunorubicin cytarabine ( ADE ) patient . III . Determine feasibility toxic effect administer postremission therapy risk adapt fashion , patient favorable cytogenetic finding receive three intensification high dose cytarabine ( HiDAC ) , average poor risk patient receive HiDAC/etoposide/filgrastim ( G-CSF ) consolidation therapy stem cell mobilization follow peripheral stem cell ( PBSC ) transplant use busulfan/etoposide preparative regimen . IV . Determine feasibility toxic effect consolidation sequence HiDAC/etoposide/G-CSF follow 2 course HiDAC patient would otherwise receive PBSC transplant , unable logistical institutional reason . V. Determine feasibility intermittent administration high dose subcutaneous interleukin-2 ( IL-2 ) combination continuous low dose subcutaneous IL-2 patient recover PBSC transplant intensive consolidation chemotherapy . OUTLINE : This dose escalation study daunorubicin induction therapy portion , separate dose escalation study etoposide portion . Patients treat three phase treatment : induction , intensification , postremission therapy . Induction therapy : Patients receive cytarabine IV continuous infusion day 1-7 plus daunorubicin IV 30 minute etoposide IV 2 hour day 1-3 ( ADE regimen ) . Some patient also receive PSC 833 IV continuous infusion day 1-3 ( ADEP regimen ) . This course may repeat 14 day later . Cohorts 9 patient receive escalate dos daunorubicin maximum tolerate dose ( MTD ) reach . The MTD define dose 3 9 patient experience dose limit toxicity . Escalations conduct separately ADE ADEP regimen . Other cohort 9 patient receive escalate dos etoposide constant dos daunorubicin ADE regimen . The MTD describe manner . Intensification therapy : Arm I ( patient certain genetic characteristic leukemia cell ) : Patients receive 3 additional course cytarabine IV 3 hour , twice day , 3 day . Courses repeat every 28 day . Arm II ( patient genetic characteristic ) : Patients undergo peripheral blood stem cell ( PBSC ) transplant . Patients first receive high dose cytarabine IV 2 hour day 1-4 , etoposide IV continuous infusion day 1-4 , filgrastim ( G-CSF ) subcutaneously begin day 5 blood count recover . PBSC collect . Approximately 4-6 week later , patient receive oral busulfan 4 time day day 1-4 etoposide IV 4 hour day 5 . PBSC reinfused day 7 . G-CSF administer subcutaneously begin day 7 blood cell count recover . Arm III ( patient undergo PBSC transplant ) : Patients receive cytarabine , etoposide , G-CSF arm II , high dose cytarabine arm I. Postremission therapy ( patient ) : Patients receive low dose interleukin-2 ( IL-2 ) daily injection 2 week . On day 15 , patient begin receive intermittent high dose IL-2 three day week . Patients alternate course IL-2 : 14 day low dose IL-2 , 3 day high dose IL-2 , 1 day rest , low dose IL-2 10 day , 3 day high dose IL-2 , 1 day rest . This course repeat 3 time . Patients receive another 16 day course low dose IL-2 . Patients follow 1 month , every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 410 patient accrue study within 36 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven acute myelogenous leukemia , except M3 PATIENT CHARACTERISTICS : Age : 15 59 Performance status : Not specify Life expectancy : Not specify Hematopoietic : No prior hematologic malignancy , myeloproliferative disorder , myelodysplastic syndrome , paroxysmalnocturnal hemoglobinuria No unexplained cytopenia great 3 month duration Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic therapy No prior treatment leukemia except leukapheresis Chemotherapy : No prior chemotherapy except hydroxyurea may use emergency therapy hyperleukocytosis Endocrine therapy : Not specify Radiotherapy : Prior cranial radiation therapy allow CNS leukostasis Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
</DOC>